<DOC>
	<DOCNO>NCT02457650</DOCNO>
	<brief_summary>Background : Autologous T cell engineer express T cell receptor ( TCR ) target NY-ESO-1 infuse back patient NY-ESO-1- express malignancy . The patient pretreated lymphodepleting precondition regimen monitor infusion anti-NY-ESO-1 TCR-transduced T cell adverse event , persistence anti-NY-ESO-1 TCR-transduced T cell treatment efficacy . Objectives : To evaluate safety efficacy anti-NY-ESO-1 TCR-transduced T cell-based immunotherapy patient NY-ESO-1- express malignancy . Eligibility : Patients older one year age , relapse refractory malignancy express NY-ESO-1 human leukocyte antigen ( HLA ) -A2 molecule . Patients must adequate organ function . Design : - Peripheral blood patient collect isolation peripheral blood mononuclear cell ( PBMCs ) , transduce lentiviral retroviral vector encode HLA-A2 restrict anti-NY-ESO-1 TCR gene . - Patients receive lymphodepleting precondition regimen prepare immune system accept modified T cell . - Patients receive infusion modify T cell . They remain hospital monitored adverse event recover treatment . - Patients frequent follow-up visit monitor persistence modify T cell efficacy treatment .</brief_summary>
	<brief_title>T Cell Receptor-transduced T Cells Targeting NY-ESO-1 Treatment Patients With NY-ESO-1- Expressing Malignancies</brief_title>
	<detailed_description>Despite advance make date treatment patient hematologic malignancy , clinical trial target solid cancer achieve limited efficacy . One important reason due lack ideal cancer antigen . NY-ESO-1 express various type cancer , include neuroblastoma , hepatoma , myeloma , melanoma , esophagus , prostate , bladder , breast ovarian cancer . While , normal somatic tissue , NY-ESO-1 expression restrict germline cell , lack HLA molecules present peptide derive NY-ESO-1 recognition T cell . Therefore , NY-ESO-1 specific T cell recognize kill NY-ESO-1-expressing cancer cell , normal cell , thus avoid induction autoimmune reaction . With unique feature , NY-ESO-1 select attractive tumor antigen candidate cancer immunotherapy various clinical trial . In trial , autologous T cell engineer express T cell receptor ( TCR ) target NY-ESO-1 infuse back patient NY-ESO-1- express malignancy receive lymphodepleting precondition regimen . The patient monitor infusion anti-NY-ESO-1 TCR-transduced T cell adverse event , persistence anti-NY-ESO-1 TCR-transduced T cell treatment efficacy . Primary objective : To determine safety feasibility administration anti-NY-ESO-1 TCR transduce T cell patient HLA-A2+ NY-ESO-1-expressing malignancy . Secondary objective : To determine treatment result clinical regression malignant tumor patient . To determine vivo persistency anti-NY-ESO-1 TCR-transduced T cell .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Must pathology cytology confirm cancer patient age one year old over； 2 . Must HLAA2 positive , cancer tissue express NYESO1； 3 . There least one measurable disease : diameter ≥20mm spiral CT≥10mm； 4 . Willing sign durable power attorney； 5 . Able understand sign Informed Consent Document； 6 . Performance status：ECOG 02； 7 . Life expectancy：More 3 months； 8 . Patients must willing practice birth control four month receive lymphodepleting precondition regimen； 9 . Patients pregnancy lactation； 10 . Hematopoietic： ( 1 ) Absolute neutrophil count ＞ 1000/mm3 without support filgrastim； ( 2 ) Platelet count ＞ 100,000/mm3； ( 3 ) Hemoglobin ＞ 8.0 g/dL； ( 4 ) lymphocyte count ＞500/mm3； ( 5 ) WBC ＞ 3,000/mm3； 11 . Chemistry： ( 1 ) AST ALT &lt; 2.5 time upper limit normal； ( 2 ) Serum creatinine≤1.6 mg/dl； ( 3 ) Bilirubin ≤1.5 mg/dL（3.0 mg/dL patient Gilbert 's syndrome）； 12 . Seronegative hepatitis B C viruses； 13 . Seronegative human immunodeficiency virus ( HIV ) antibody； 14 . More four week must elapse since prior systemic therapy time randomization , patient ' toxicity must recover grade 1 less ( except alopecia vitiligo ) . Patients may undergo minor surgical procedure within past 3 week , long toxicity recover grade 1 less specify eligibility criteria； 15 . Six week must elapse since prior antiCTLA4 antibody therapy allow antibody level decline . Patients previously receive antiCTLA4 antibody document gastrointestinal ( GI ) toxicity must normal colonoscopy normal colonic biopsy . 1 . Any form primary immunodeficiency ( Severe Combined Immunodeficiency Disease ) ； 2 . Active systemic infections； 3 . Coagulation disorder major medical illness cardiovascular , respiratory immune system； 4 . Concurrent use systemic steroids； 5 . History severe immediate hypersensitivity reaction agent use study； 6 . There obvious dysfunction heart , liver，kidney vital organ 7 . T cell lymphoma leukemia patients； 8 . HIV positive； 9 . History coronary revascularization ischemic symptoms； 10 . Documented Left Ventricular Ejection Fraction ( LVEF ) less equal 45 percent test patient : Clinically significant atrial and/or ventricular arrhythmia include limited : atrial fibrillation , ventricular tachycardia , second third degree heart block； 11 . Documented forced expiratory volume 1 ( FEV1 ) less equal 60 percent predict tested patient prolonged history cigarette smoking ( 20 pk/yrs smoke ) symptom respiratory dysfunction； 12 . Bronchial lesion ( probably shift obstructive pneumonia intracranial hemorrhage risk )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>